抗凝固药与免疫抑制疗法结合使用是否可以预防贝赫塞特病的复发性血栓形成?
Serhat Erol1, Aslıhan Gürün Kaya1, Fatma Arslan1
1Chest Diseases Department, Ankara University, Ankara, Turkey.
概括
将抗凝剂 (AC) 添加到免疫抑制剂 (IS) 中,显著减少了Behçet的复发性血栓形成.
科学领域:
- 类风湿病学 类风湿病学
- 血管医学 血管医学
- 免疫学 免疫学 免疫学
背景情况:
- 贝塞特病 (BD) 经常涉及血管并发症,血栓形成是主要问题.
- 炎症在BD中驱动血栓形成,使免疫抑制剂 (IS) 成为标准治疗.
- 与IS一起的抗凝血 (AC) 在管理BD相关血栓的作用仍在争论中.
研究的目的:
- 对免疫抑制疗法 (IS) 添加抗凝剂 (AC) 在降低贝赫特病 (BD) 中复发性血栓事件的疗效进行研究.
- 为了比较静脉血栓栓塞 (VTE) 复发率,BD患者仅用IS治疗,而不是IS加AC.
主要方法:
- 对40名经历了血栓事件的贝切特病患者的回顾性分析.
- 复发性静脉血栓栓塞 (VTE) 发生率的比较,单独接受免疫抑制剂 (IS) 和接受IS与抗凝药 (AC) 结合治疗的患者之间.
主要成果:
- 共有22名患者 (55%) 经历了27次复发的VTE事件.
- 在IS+AC组中,复发率明显低于IS单独组 (55.5%) 的复发率 (7.4%).
- 深静脉血栓和肺栓塞是最常见的最初血管事件.
结论:
- 免疫抑制剂 (IS) 是贝塞特病 (BD) 治疗的基石.
- 在IS治疗中添加抗凝剂 (AC) 可能显著降低BD患者复发性血栓事件的风险.
- 需要进一步的前性研究来证实这些发现.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523